Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced PatientsReport as inadecuate




Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients - Download this document for free, or read online. Document in PDF available to download.

Canadian Journal of Gastroenterology and Hepatology - Volume 2016 2016, Article ID 2872371, 7 pages -

Clinical Study

Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, MBC-11, P.O. Box 3354, Riyadh 11211, Saudi Arabia

Alfaisal University, College of Medicine, Riyadh, Saudi Arabia

Liver and Small Bowel Transplant and Hepatobiliary and Pancreatic Surgery-Organ Transplant Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

King Saud University, College of Medicine, Riyadh, Saudi Arabia

Received 3 November 2015; Accepted 10 November 2015

Copyright © 2016 A. Ajlan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background and Aim. This is an open label prospective cohort study conducted at a tertiary care hospital. The primary endpoint is SVR12 in patients treated with sofosbuvir-based therapy in post-liver transplant patients with genotype 4 HCV recurrence. Methodology. Thirty-six treatment-experienced liver transplant patients with HCV recurrence received sofosbuvir and ribavirin ± peginterferon. Results. We report here safety and efficacy data on 36 patients who completed the follow-up period. Mean age was 56 years, and the cohort included 24 males and one patient had cirrhosis. Mean baseline HCV RNA was 6.2 log10 IU-mL. The majority of patients had ≥ stage 2 fibrosis. Twenty-eight patients were treated with pegylated interferon plus ribavirin in addition to sofosbuvir for 12 weeks and the remaining were treated with sofosbuvir plus ribavirin only for 24 weeks. By week 4, only four 11.1% patients had detectable HCV RNA. Of the 36 patients, 2 5.5% relapsed and one died 2.75%. Conclusion. Our results suggest that sofosbuvir + ribavirin ± pegylated interferon can be utilized successfully to treat liver transplant patients with HCV recurrence.





Author: A. Ajlan, A. Al-Jedai, H. Elsiesy, D. Alkortas, W. Al-Hamoudi, R. Alarieh, M. Al-Sebayel, D. Broering, and F. Aba Alkhail

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents